Related Experiment Video

Updated: May 2, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation

Eva C I Woelders1, Bahram Yosofi1, Denise A M Peeters1

  • 1Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.

American Heart Journal
|April 30, 2026
PubMed

Insights

Ticagrelor monotherapy after primary PCI showed similar ischemic event rates compared to dual antiplatelet therapy (DAPT) in STEMI patients. Bleeding events were numerically lower with ticagrelor monotherapy, but safety requires further study.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Dual antiplatelet therapy (DAPT) is standard after percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
  • Ticagrelor monotherapy is being explored as an alternative to reduce bleeding risk.
  • Assessing the safety and efficacy of ticagrelor monotherapy post-PCI is crucial.

Purpose of the Study:

  • To evaluate the safety of ticagrelor monotherapy versus DAPT in STEMI patients undergoing primary PCI.
  • To compare major adverse cardiac and cerebral events (MACCE) and bleeding events between the two strategies.

Main Methods:

  • A randomized, multicenter, open-label pilot study.
  • 200 STEMI patients were randomized to ticagrelor monotherapy or DAPT after primary PCI.
  • Outcomes assessed included MACCE, clinically relevant bleeding, and clinically relevant non-access site bleeding at three months.

Main Results:

  • No significant difference in MACCE between ticagrelor monotherapy (3.1%) and DAPT (2.0%) groups.
  • Clinically relevant bleeding was lower in the ticagrelor monotherapy group (4.2%) compared to DAPT (8.9%).
  • Clinically relevant non-access site bleeding was significantly lower with ticagrelor monotherapy (2.0%) versus DAPT (7.9%).

Conclusions:

  • Ticagrelor monotherapy did not show a significant difference in ischemic events compared to DAPT in STEMI patients.
  • A trend towards reduced bleeding events, particularly non-access site bleeding, was observed with ticagrelor monotherapy.
  • Larger studies are needed to confirm the safety and efficacy of ticagrelor monotherapy due to the small number of events in this pilot study.
Abstract

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.0K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

722

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
18